In vitro and in vivo pharmacological characterization of SSD114, a novel GABAB positive allosteric modulator.

  title={In vitro and in vivo pharmacological characterization of SSD114, a novel GABAB positive allosteric modulator.},
  author={Alessandra Porcu and Carla Lobina and Daniela Giunta and Maurizio Solinas and Claudia Mugnaini and Maria Paola Castelli},
  journal={European journal of pharmacology},
Positive allosteric modulators (PAMs) of the GABAB receptor have emerged as a novel approach to the pharmacological manipulation of the GABAB receptor, enhancing the effects of receptor agonists with few side effects. Here, we identified N-cyclohexyl-4-methoxy-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine (SSD114) as a new compound with activity as a GABAB PAM in in vitro and in vivo assays. SSD114 potentiated GABA-stimulated [35S]GTPγS binding to native GABAB receptors, whereas it had no… Expand
COR758, a negative allosteric modulator of GABAB receptors
The characterization of COR758 is reported, which acts as GABABR NAM in rat cortical membranes and CHO cells stably expressing GABABRs (CHO-GABAB) and might serve as a scaffold to develop additional NAMs for therapeutic intervention. Expand
Structure optimization of positive allosteric modulators of GABAB receptors led to the unexpected discovery of antagonists/potential negative allosteric modulators.
A number of them significantly inhibited GABA-stimulated GTPγS binding thus revealing a functional switch with respect to the prototype molecules, and further studies on selected compounds will clarify if they act as negative modulators of the receptor or, instead, as antagonists at the orthosteric binding site. Expand
Ligand-guided homology modelling of the GABAB2 subunit of the GABAB receptor
This study is the first to describe homology modelling of the transmembrane domain of the GABAB2 subunit and the docking of positive allosteric modulators in the receptor. Expand
Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gαi/o protein inhibitor
It is shown that micromolar concentrations of rimonabant inhibited G&agr;i/o‐type G proteins, resulting in a receptor‐independent block of G protein signaling, which may help to understand its pharmacological and toxicological effects occurring at high concentrations. Expand


Characterization of COR627 and COR628, Two Novel Positive Allosteric Modulators of the GABAB Receptor
Two novel compounds, COR627 and COR628, may represent two additional tools for use in investigating the roles and functions of positive allosteric modulatory binding sites of the GABAB receptor. Expand
diamine (GS39783) and Structurally Related Compounds: Novel Allosteric Enhancers of -Aminobutyric Acid B Receptor Function
N,N-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6- diamine (GS39783) and structurally related compounds are de- scribed as novel allosteric enhancers of GABAB receptor function. TheyExpand
In vivo effectiveness of CGP7930, a positive allosteric modulator of the GABAB receptor.
Assessment of the in vivo effectiveness of the positive allosteric modulator of the gamma-aminobutyric acidB (GABAB) receptor, CGP7930, confirms that it may constitute an interesting tool for pharmacological studies in the GABAB receptor field. Expand
Synthesis and pharmacological characterization of 2-(acylamino)thiophene derivatives as metabolically stable, orally effective, positive allosteric modulators of the GABAB receptor.
Although displaying a lower potency in vitro than the reference compound GS39783, the new compounds 6, 10, and 11 exhibited a higher efficacy in vivo: combination of these compounds with a per se nonsedative dose of baclofen resulted in shorter onset and longer duration of the loss of righting reflex in mice. Expand
In vitro and in vivo characterization of the novel GABAB receptor positive allosteric modulator, 2-{1-[2-(4-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-2-piperidinyl}ethanol (CMPPE)
The in vitro profile of a novel chemical structure, 2-{1-[2-(4-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-2-piperidinyl}ethanol (CMPPE) identified by screening the GSK compound collection is reported and it is demonstrated that GABA(B) receptor PAMs may represent a novel pharmacological approach to treat eating disorders without unwanted sedative effects. Expand
Behavioral Characterization of the Novel GABAB Receptor-Positive Modulator GS39783 (N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): Anxiolytic-Like Activity without Side Effects Associated with Baclofen or Benzodiazepines
The data obtained here suggest that positive modulation of GABAB receptors may serve as a novel therapeutic strategy for the development of anxiolytics, with a superior side effect profile to both baclofen and benzodiazepines. Expand
GABAB Receptor-Positive Modulators: Enhancement of GABAB Receptor Agonist Effects In Vivo
Examining the in vivo positive modulatory properties of the GABAB receptor-positive modulators provides evidence that CGP7930 and rac-BHFF act in vivo as positive modulators at GABAB receptors mediating loss of righting, but not at neurons mediating hypothermia. Expand
Positive regulation of GABA(B) receptors dually coupled to cyclic AMP by the allosteric agent CGP7930.
Data indicate that CGP7930 positively modulates brain GABA(B) receptors coupled to either stimulation or inhibition of cyclic AMP signalling. Expand
Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501.
It is shown that CGP7930 enhances the inhibitory effect of L-baclofen on the oscillatory activity of cultured cortical neurons and may represent a novel means of therapeutic interference with the GABA-ergic system. Expand
Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies.
Functional studies confirm that brucine analogs are allosteric enhancers of ACh affinity at certain muscarinic receptor subtypes. Expand